The Ets-domain transcription factor PU.1 is key to myeloid and B-cell development as well as to hematopoietic stem cell maintenance by controlling differentiation, proliferation and survival of these cells. During myelopoiesis PU.1 activates a large number of genes directly involved in myeloid differentiation and maturation. [1] [2] [3] Importantly, PU.1 levels are crucial for the determination of the different hematopoietic lineages. 4 In malignant hematopoiesis deregulated elevated PU.1 expression causes erythroleukemia in mice, whereas reduced PU.1 expression leads to leukemia and lymphomas. 3 In line with these findings in mice, low PU.1 levels are found in undifferentiated human acute myeloid leukemia (AML), particularly in acute promyelocytic leukemia (APL) where PU.1 is transcriptionally repressed by the PML-RARA fusion protein. 5, 6 In addition to its role in controlling myeloid differentiation, PU.1 directly or indirectly regulates genes implicated in apoptosis and proliferation. For instance, PU.1 can attenuate Bim's proapoptotic activity by directly inducing MEIS1 positively affecting AML cell proliferation. 7 Moreover, PU.1 directly activates antiapoptotic Bcl-2A1 to support cell survival during neutrophil differentiation. 8 The role of PU.1 can be extended to the commitment and maintenance of stem cells trough regulating the transcription of several cell cycle regulators. 9 Recently, we linked PU.1 to the intracellular degradation process autophagy during retinoic acid-induced neutrophil differentiation of AML cells. [10] [11] [12] Taken together, these reports clearly highlight the importance and versatility of this transcription factor in regulating apoptotic and cell cycle genes in a context-dependent manner.
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising anticancer drug because of its capacity to induce apoptosis selectively in cancer cells. 13 TRAIL is a member of the TNF family of death ligands and binds to the four major receptors TRAIL-R1-4. Binding to TRAIL-R1 (DR4) and TRAIL-R2 (DR5) induces apoptosis signaling, whereas binding to TRAIL-R3 (DcR1) and TRAIL-R4 (DcR2) can impair apoptosis signaling and activate alternative, non-apoptotic pathways.
14,15 TRAIL binding to DR4 and DR5 triggers the formation of the death-inducing signaling complex (DISC), characterized by the recruitment of the adaptor protein FADD and caspase-8, which then induce the activation of downstream effector caspases. 16 Resistance of cancer cells to TRAIL monotherapy is commonly found and includes increased expression of antiapoptotic genes such as the NF-κB target genes cellular FLICE-inhibitory protein (cFLIP), Bcl-2 and Mcl-1. [17] [18] [19] [20] Alternatively, upregulation of decoy receptor expression (TRAIL-R3) paralleled by NF-κB pathway activation increases resistance to TRAIL. 21, 22 To date, the function of PU.1 in leukemia therapy other than differentiation therapy in APL has not been investigated in detail. We found that PU.1 enhances cell death responses to TRAIL and anthracycline treatment. Mechanistically, PU.1 was found to inhibit NF-κB signaling by its interaction with RelA/p65 and thereby preventing the induction of antiapoptotic genes. Moreover, we identified DR5 as a critical transcriptional target of PU.1 in response to TRAIL. Altogether, our studies identify PU.1 as a novel cell death regulator during AML therapy.
Results
PU.1 depletion increases the resistance to TRAILmediated apoptosis in AML cells. Based on the emerging role of PU.1 in physiological cell survival and apoptosis, we asked whether inhibiting PU.1 affects cellular fitness upon exogenous apoptosis stimulation by TRAIL treatment. We generated three different PU.1-knockdown AML cell lines, namely NB4, HL60 and MOLM-13 cells using two independent PU.1 targeting short hairpin RNA (shRNA) delivered by lentiviral vectors. PU.1-depleted and control-transduced AML cells were treated with human recombinant TRAIL for 24 h. NB4 cells showed the lowest TRAIL sensitivity as compared with the other two AML cell lines and TRAIL concentrations for treatment were adapted to reach similar death responses (Supplementary Figures S1a-c; control cells). TRAIL treatment caused increased early apoptosis in control-transduced AML cells as evidenced by high levels of Annexin V + cells (35-45%), whereas PU.1 depletion resulted in a significant reduction of Annexin V + cells (15-25%) that prevailed at higher TRAIL concentrations ( Figure 1a and Supplementary Figures S1a-d) . In addition, all three AML PU.1-depleted cell lines showed a significant reduction in effector caspases activation as assessed by the caspase-3/7 activity (Figure 1b and Supplementary Figure S1d ; lower panel). These findings were not restricted to AML cells, and also extend to an REH B-cell precursor leukemia cell line (Supplementary Figure S1e) .
Next, we determined cleaved caspase-8 and -3, and cleaved PARP protein levels. Upon TRAIL treatment, NB4 and HL60 PU.1-depleted cells showed markedly reduced caspase-8 cleavage paralleled by increased procaspase-8 levels as compared with control cells (Figure 1c and Supplementary Figure S2a) . Accordingly, PU.1-knockdown cells showed a marked reduction in caspase-3 and PARP cleavage, confirming reduced apoptosis in PU.1-knockdown cells. These results were validated in MOLM-13 cells (Supplementary Figure S2b) . Moreover, specifically inhibiting Bcl-2 by ABT-199 did only partially restore sensitivity of PU.1-depleted AML cells to TRAIL in NB4 but not in HL60 cells, indicating that decreased PU.1 levels impact on TRAIL sensitivity mostly at the level of the DISC (Supplementary Figure S3) . Altogether, we found impaired apoptosis responses to TRAIL in PU.1-depleted leukemic cells.
Decreased sensitivity to TRAIL in PU.1-depleted AML cells is associated with increased NF-κB activity. Given that TRAIL can induce alternative, prosurvival pathways such as NF-κB signaling and since we observed reduced sensitivity to TRAIL-induced apoptosis in PU.1-knockdown cells, we hypothesized that depleting PU.1 activates NF-κB signaling. To test this hypothesis, we transfected NB4 and HL60 cells with an NF-κB reporter plasmid. We found significantly increased NF-κB activity in PU.1-depleted AML as compared with control cells (Figure 2a) . We next assessed whether cytoplasmic and nuclear protein lysates revealed a significantly pronounced nuclear translocation of p65 after 1 h of TRAIL stimulation in PU.1-depleted cells as compared with control NB4 cells (Figure 2b and Supplementary Figure S4) . As AML PU.1-knockdown cells display increased NF-κB activity, we speculated that blocking the NF-κB pathway restores TRAIL sensitivity. Indeed, pretreating NB4 PU.1-knockdown cells with two different NF-κB inhibitors JSH-23 (blocks p65 nuclear translocation) or BAY 11-7085 (blocks IκBα phosphorylation) was found to partially restore TRAIL sensitivity of these cells (Figure 2c ).
PU.1 binds to p65 and represses NF-κB activity. We next asked if PU.1 might directly interfere with the NF-κB pathway via p65. First, we observed co-precipitation of exogenously expressed PU.1 with FLAG-tagged p65 in H1299 cells. In addition, immunoprecipitation of exogenously expressed FLAG-tagged PU.1 co-precipitated endogenous p65 in the same cells (Figure 3a) . Thus, our data indicate a new PU.1 and p65 protein-protein interaction. Further, to test if PU.1 and p65 interactions also occur at the endogenous level in AML cells, we used proximity ligation assay (PLA). A positive signal in PLA indicates that these two proteins are in close proximity (o40 nm) in situ. Indeed, endogenous PU.1 and p65 interact in two different AML cell lines (Figure 3b) . These results suggest a novel PU.1-p65 protein interaction whereby PU.1 might directly regulate the prosurvival functions of the NF-κB signaling pathway.
As we observed increased NF-κB activity in PU.1-knockdown cells, and that PU.1 and p65 interact, we investigated whether PU.1 represses NF-κB/p65 activity. To evaluate this possibility, PU.1-negative H1299 cells were co-transfected with increasing amounts of PU.1 and an NF-κB luciferase reporter plasmid. In these cells, we observed a significant, dose-dependent decrease of NF-κB reporter activity with increasing amounts of transfected PU.1 (Figure 3c Figure S5c) . Overall, these results suggest that the levels of several antiapoptotic proteins are less affected in TRAIL-treated PU.1-knockdown as opposed to AML control cells. Furthermore, increased levels of antiapoptotic genes likely contribute to the resistance mechanisms against TRAIL in PU.1-depleted cells.
PU.1-depleted cells (Supplementary
TRAIL resistance in PU.1-depleted AML cells is associated with TRAIL receptor DR5 downregulation. As NF-κB pathway inhibition did not completely rescue the PU.1-knockdown phenotype and since resistance to TRAIL treatment is frequently associated with aberrant low expression of activating TRAIL receptors, we investigated if PU.1 levels are associated with TRAIL-activating receptor DR5 expression. As increased DR5 protein expression alone does not imply functional DR5 at the cell surface, we also determined DR5 surface expression by FACS analysis. First, we determined steady-state DR5 expression in all three AML cell lines used in this study. HL60 cells expressed the highest DR5 levels in accordance with being the most TRAIL-sensitive cell line followed by MOLM-13 and NB4 cells (Supplementary Figure S6a) . DcR2 mRNA levels showed a similar pattern as DR5, whereas DR4 and DcR1 levels did not parallel PU.1 expression (Supplementary Figure S6b) . Figure S7c) . PU.1 and p65 chromatin immunoprecipitation (ChIP) confirmed binding of both transcription factors to a DNA region with neighboring PU.1-and p65-binding sites (Figure 5e ). Using an inducible PU.1-estrogen receptor fusion protein (PU.1-ER) to specifically induce PU.1 target genes, 25 we found a significant, 3-4-fold increase in DR5 mRNA expression paralleled by a marked increase in DR5 protein expression after 4-hydroxytamoxifen stimulation (Figure 5f and Supplementary Figure S7d) . Importantly, activation of PU.1 did not induce DR4 transcription, whereas G-CSF-R mRNA, a known PU.1 target, 26 expression in all three AML cell lines investigated likely contributing to the observed decreased sensitivity to TRAIL. As depleting PU.1 only resulted in reduced DR4 mRNA levels in untreated NB4 cells and DR4 transcription was not induced by PU.1 activation in two AML cell lines, we speculate that DR4 is not a direct transcriptional target of PU.1. Given that PU.1 knockdown causes partial resistance to TRAIL and that inducing PU.1 resulted in increased DR5 surface expression, we next evaluated whether inducing PU.1 would sensitize AML cells to TRAIL-induced cell death. Indeed, activation of PU.1 resulted in a significantly higher percentage of Annexin V + cells upon TRAIL treatment (Figure 5g) . Importantly, induction of PU.1 alone without TRAIL treatment already resulted in increased cell death as evidenced by increased Annexin V staining and increased levels of cleaved PARP (Figure 5h, upper panels) . In addition, activation of PU.1 upon TRAIL treatment attenuated the expression of FLIP S , BCL-2 and MCL-1, all proteins whose expression increases upon PU.1 depletion (Figure 5h , lower panels). Interestingly, PU.1 expression resulted in a shift toward the expression of FLIP L . These results suggest that PU.1 exerts a proapoptotic role by upregulating DR5 and causing lower expression of several antiapoptotic proteins.
PU.1 depletion protects from anthracycline-mediated apoptosis. Current AML therapy does not include TRAIL, but is based on the use of the anthracyclines. 27 Thus, we asked whether the absence of PU.1 attenuated intrinsic apoptotic pathways as well. We incubated wild-type and PU.1-depleted AML cells with the anthracyclines doxorubicin or idarubicin, and then assessed cell viability by Annexin V staining and caspase-3/7 activity. Similar to TRAIL treatment, knocking down PU.1 resulted in a significant apoptosis inhibition as compared with wild-type cells treated with either doxorubicin or idarubicin, which was supported by a marked decrease in caspase-3 and PARP cleavage (Figure 6a ). Most importantly, as with TRAIL treatment of PU.1-depleted cells, treatment with both anthracyclines resulted in persistent expression of the antiapoptotic proteins XIAP, BCL-2 and MCL-1 (Figure 6b) . Importantly, blocking Bcl-2 with the BCL-2-selective inhibitor ABT-199 restored sensitivity to anthracyclines underlining the relevance of Bcl-2 in resistance mechanisms towards chemotherapeutics in PU.1-depleted AML cells (Figure 6c ). In conclusion, PU.1 supports anthracycline-mediated cell death in AML cells.
Discussion
The key finding of this study is the novel function of PU.1 in cell death responses to clinically relevant drugs in AML cells. Mechanistically, PU.1 significantly prevents NF-κB-mediated upregulation of antiapoptotic genes such as cFLIP, MCL-1, BCL-2 and BCL-XL upon TRAIL treatment. We showed for the first time that PU.1 directly binds to RelA/p65 and thereby represses the transcriptional activity of p65. In addition, PU.1 contributes to TRAIL sensitivity by directly inducing TRAIL receptor DR5 transcription. Overall, our findings further expand the function of the PU.1 transcription factor to cell death responses towards anticancer therapies.
The effects of PU.1 and NF-κB are tightly linked as they interdependently regulate gene transcription by binding to the same promoter regions of common target genes. The combined actions of these two transcription factors might have synergistic activating or inhibiting functions. Moreover, NF-κB directly regulates PU.1 at the transcriptional level by binding to the 5'-URE of the PU.1 gene. 28 PU.1 affects, together with C/EBPα, NF-κB target selection in THP-1 cells by mediating the formation of active protein complexes at the enhancer region of target genes. 29 In addition, the NF-κB1/p50 promoter is directly regulated by PU.1 and transcriptional family member, Spi-B. 30 Given that another myeloid transcription factor, C/EBPα, interacts with the NF-κB pathway proteins to induce expression of the antiapoptotic BCL-2 in AML, 31 we asked whether PU.1 also directly interacts with this survival pathway. We were able to co-precipitate endogenous RelA/p65 with FLAG-tagged PU.1 expressed in H1299 cells. The direct interaction of endogenous RelA/p65 and PU.1 was shown by an in situ PLA. In contrast to our findings, Shen and Stavnezer 32 used PU.1 as a specificity control for their GST-pull-down assay to show p65 and STAT6 interaction. GST-p65 did not pull down PU.1 from 1.29 μ B-lymphoma cell nuclear extracts. This discrepancy may be due to the use of more sensitive in vitro assays or may reflect differences in B-lymphoma versus AML cells.
Using an NF-κB reporter consisting of a concatemer of NF-κB-binding motifs and an MCL-1 promoter reporter with an NF-κB-binding site, we found that PU.1 negatively impacts on NF- κB's capacity to activate transcription. Furthermore, NF-κB promotes cell survival through the activation of several antiapoptotic genes including FLIP, 33 Mcl-1 34 or XIAP.
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Consistently, we showed that increased expression of NF-κB-regulated antiapoptotic genes in PU.1-depleted AML cells that contributed to the resistance phenotype against TRAIL. The resistance seen in PU.1-depleted AML cells can partially be overcome by using NF-κB inhibitors in combination with TRAIL. Furthermore, using a tamoxifen-inducible PU.1 overexpression system, we found that activation of PU.1-sensitized NB4 cells to TRAIL. Of note, activation of PU.1 per se did induce significant cell death possibly by activating endogenous TRAIL (Figure 5g ). In agreement with our data, Tatetsu et al. 36 observed a similar effect in U266 myeloma cells using a tetracycline-inducible PU.1 overexpression system. Induction of PU.1 resulted in increased cell death of U266 cells paralleled by decreased expression of antiapoptotic Bcl-XL and BCL-2A1 proteins as well as increased levels of cleaved caspase-3.
It is rather intriguing that PU.1 directly or indirectly activates pro-or antiapoptotic factors depending on the cell type and cellular context. For example, on the one hand, PU.1 attenuates Bim transcription, which in turn promotes apoptosis resistance in leukemia, 7 and on the other hand, PU.1 directly activates TRAIL transcription leading to cell death in myeloma cells. 37 Here, we provide evidence that PU.1 transcriptionally regulates the TRAIL receptor DR5 leading to a significant increase in DR5 surface expression and increased TRAIL sensitivity. This direct activation of the DR5 adds this gene to the list of proapoptotic genes under the control of PU.1. Alternatively, persistent expression of decoy receptor DcR2 (TRAIL-4) or decreased expression of DR4 as found in PU.1-depleted NB4 cells upon TRAIL treatment may contribute to the decreased TRAIL responsiveness in particular cell types ( Supplementary Figures S6d and S8a) .
PU.1 also interacts with and attenuates transcriptional activity of the proapoptotic p53 tumor suppressor, 38 a feature that might contribute to erythroleukemia development where untimely expression of PU.1 leads to a failure in erythroid differentiation. In this study, depleting PU.1 rendered p53 wildtype (MOLM-13), p53 mutant (NB4) as well as p53-null (HL60) AML cells less sensitive toward TRAIL treatment. This indicates that p53-independent mechanisms contribute to PU.1-mediated cell death responses to TRAIL as well as to anthracycline treatment. An earlier report from our group described the antiapoptotic BCL-2A1 as a direct transcriptional target of PU.1 that contributes to the survival of granulocytes during all-trans-retinoic acid (ATRA)-induced neutrophil differentiation of APL cells. 8 Accordingly, specifically knocking down Bcl2a1a and not Bcl2a1b/d in the murine hematopoietic system resulted in increased spontaneous cell death in granulocytes. 39 Thus, we suggest a rather specific role for BCL-2A1 in hematopoietic cell survival upon terminal differentiation. Nevertheless, BCL-2A1 is a direct transcriptional target of NF-κB and can substitute for NF-κB to suppress TNFα-induced apoptosis, and we cannot exclude that it is involved in modulating PU.1-controlled cell survival upon TRAIL treatment. 40 Overall, we propose that cellular context regulates PU.1 function in balancing the expression of prosurvival and antiapoptotic genes.
Importantly, decreased sensitivity of PU.1-knockdown cells was not only observed during TRAIL but also during conventional chemotherapy treatment (idarubicin, doxorubicin) of AML cells. Similar to TRAIL treatment, we observed persistent expression of the antiapoptotic proteins XIAP, BCL-2 and MCL-1 in PU.1-depleted cells (Figure 6 ). These data are supported by earlier data from Zhao et al. 41 showing that knocking down PU.1 in U937 AML cells allowed for BCL-2 expression upon etoposide treatment. The resistance against different death stimuli in PU.1-depleted cells strongly suggests a more general function of PU.1 in regulating not only extrinsic but also intrinsic apoptosis as engaged by DNA-damaging agents.
In this study, we investigated the role of PU.1 in cell death mediated by anticancer therapies and found that PU.1 exerts proapoptotic functions by repressing the prosurvival function of NF-κB and by increasing death receptor DR5 expression. The overall outcome on cell death upon PU.1 depletion in all AML cell lines investigated is similar, but we speculate that the three cell lines differ to which extent they engage PU.1-dependent NF-κB inhibition or DR5 upregulation to increase TRAIL sensitivity (Supplementary Figure S8b) . Reactivation of PU.1 in AML cells may represent an interesting strategy for sensitizing these cells to current cytotoxic therapies. Since ATRA can restore PU.1 expression in APL cells and can also induce TRAIL expression, and combination therapies with TRAIL and ATRA might be of interest. 5, 42 Alternatively, the use of NF-κB inhibitors in combination with TRAIL may represent an intriguing treatment option. These inhibitors are currently not used in the clinics due to their strong side effects. 43 Nevertheless, NF-κB inhibitors might still be a valuable option when used at lower doses and in combination with other drugs during a short therapeutic window. Taken together, our findings may provide useful information for the development of alternative therapeutic strategies in AML by modulating the PU.1 pathway.
Materials and Methods
Cell lines and culture conditions. The human AML NB4, HL60 and MOLM-13 as well as the B-ALL REH and the non-small-cell lung cancer H1299 cell lines were maintained in RPMI-1640 (Sigma-Aldrich, Switzerland) supplemented with 10% FBS (no. S0615; Biochrom GmbH, Germany) and 1% penicillin/ streptomycin (P4333; Sigma-Aldrich). Cells were cultured in a humidified atmosphere containing 5% CO 2 at 37°C. The human embryonic kidney 293T cells were cultured in DMEM (Sigma-Aldrich) supplemented with 5% FBS, 1% penicillin/streptomycin and 1% HEPES (Sigma-Aldrich), and kept in a humidified atmosphere containing 7.5% CO 2 at 37°C.
Transient transfections and reporter assays. H1299 cells were transiently transfected with pGL4-NFκB (Promega AG, Switzerland) or pGL2-Mcl-1 (Addgene plasmid no. 19132) Firefly luciferase reporter plasmid using Lipofectamine (Invitrogen, Switzerland). NB4 and HL60 cells were transiently transfected with pGL4-NFκB (Promega) using nucleofection (no. VCA-1003; Lonza Group Ltd, Switzerland). Cells were lysed for 24 h (Lipofectamine) or 5 h (Nucleofection) after transfection and assayed for luciferase activity using the DualGlo Luciferase Assay Kit (Promega). Firefly luciferase activity was normalized to that of Renilla luciferase expressed from the co-transfected pGL-Renilla plasmid. Results, expressed as ratio of Firefly to Renilla luciferase (relative luciferase activity), are the means of three independent experiments measured in triplicate. Error bars represent standard deviations.
Generation of PU.1-knockdown and PU.1-ER-expressing cell lines. pLKO.1 lentiviral vectors expressing shRNAs targeting PU.1 (shPU.1_256: NM_003120.1-256s1c1/TRCN0000020536 and shPU.1_928: NM_003120.1-928s1c1/TRCN0000020538), or a nontargeting shRNA control (SHCOO2) were purchased from Sigma-Aldrich and have been validated earlier. 11, 44, 45 The retroviral pBabe-PUER-puro vector (kindly provided by Dr. H Yoshida) was co-transfected with the pCl10A1 packaging construct to generate recombinant retrovirus. Lentiviral and retroviral transductions were carried out as described. 44, 46 All vectors contain a puromycin antibiotic resistance gene for selection of transduced mammalian cells. Transduced cells were selected for 4 days using 1.5 μg/ml puromycin. 
